ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...
Investor's Business Daily on MSN1h
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal SprayARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.
Madison WMTV on MSN16h
Raising awareness and funds for ALK-Positive lung cancerA fundraiser for a rare genetic form of lung cancer happened Sunday, raising money for greater research and awareness of the ...
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline ...
Under the latest deal, ARS is in line to receive up to $320 million in regulatory and sales milestones, plus tiered, double-digit royalties in the teens on net sales in places where ALK will market ...
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK ...
In the past week, Alaska Air Group ALK and SkyWest SKYW reported better-than-expected earnings per share and revenues for the ...
US Bancorp DE reduced its holdings in Alaska Air Group, Inc. (NYSE:ALK – Free Report) by 2.9% in the 3rd quarter, according ...
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback